http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101939005-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-61
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2008-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ba1a3c5839133cc603d0299de45dcab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b6386e9e4856113046f73baa99457ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cc1d7cc06bd6744ce7516636b8121ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2310333a8479c5c687160e281fcd1da5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b33b9187c9afed09657af5e03a9c9b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abd31a6335bdc1794249720af3460c25
publicationDate 2011-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-101939005-A
titleOfInvention Kinesin inhibitors as cancer therapeutics
abstract The invention provides novel imidazole compounds that inhibit the activity of kinesin spindle protein (KSP, also called Eg5). Inhibitors of KSP can reduce undesired cellular proliferation and provide other therapeutic effects. The invention also provides pharmaceutical compositions containing these novel compounds, and methods of using the novel KSP inhibitors and their pharmaceutical compositions to treat various types of cancers. The compounds, compositions and methods of the invention are especially useful for treating certain classes of cancers that are resistant to conventional drug treatments, because such cancers are shown to remain sensitive to the compounds of the invention.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111529526-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110719906-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110719906-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109646679-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106668863-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106668863-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105646361-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105646361-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111954532-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105418527-A
priorityDate 2007-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467839082

Total number of triples: 33.